GlassScriptPhysician profile
Dhaval Patel
NPI 1679064026
$3,144.47
in general payments reported to CMS, 2019-2025
26 companies · $466 in 2025
The $466 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.45 · 2021: $14.64 · 2023: $208 · 2024: $2,356 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,525 · Food and Beverage: $993 · Travel and Lodging: $313 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,525.00 |
| Food and Beverage | $993.43 |
| Travel and Lodging | $313.00 |
| Education | $198.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,893.00 | 2024 | |
| Aveo Pharmaceuticals, INC. | $160.58 | 2023-2024 | Fotivda |
| Amgen INC. | $143.64 | 2023-2025 | Repatha, Xgeva, Nplate |
| E.R. Squibb & Sons, L.L.C. | $136.80 | 2023-2025 | Reblozyl, Opdivo |
| Teva Pharmaceuticals USA, INC. | $99.45 | 2019 | |
| Astellas Pharma US INC | $99.00 | 2024 | |
| Janssen Biotech, INC. | $75.24 | 2023-2025 | Erleada, Tremfya, Darzalex |
| Ipsen Biopharmaceuticals, INC | $70.70 | 2024-2025 | Dysport, Onivyde |
| Merck Sharp & Dohme LLC | $56.42 | 2024 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $47.71 | 2024-2025 | Ninlaro |
| Puma Biotechnology, INC. | $36.08 | 2025 | |
| Eisai INC. | $33.68 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.81 | 2024-2025 | |
| Stemline Therapeutics INC. | $30.23 | 2024-2025 | Orserdu |
| Novocure INC. | $25.12 | 2025 | Optune Lua (Novottf-200t) |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23.95 | 2024 | Zejula, Jemperli |
| Pfizer INC. | $21.68 | 2025 | |
| Ucb, INC. | $20.52 | 2025 | Bimzelx |
| Mallinckrodt Hospital Products INC. | $19.03 | 2025 | Acthar |
| Myriad Genetic Laboratories, INC. | $18.91 | 2025 | Myrisk |
| Exelixis INC. | $18.60 | 2025 | Cabometyx |
| Telix Pharmaceuticals | $17.91 | 2025 | Illuccix |
| Deciphera Pharmaceuticals INC. | $17.50 | 2025 | Qinlock, Romvimza |
| Abbvie INC. | $17.00 | 2025 | |
| Blueprint Medicines Corporation | $16.27 | 2025 | Ayvakit |
| Kowa Pharmaceuticals America, INC. | $14.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dhaval Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.